A Phase Ib Study of HS-10504 Combined Therapy in NSCLC

Prior treatment

• Insufficient wash out duration of prior systemic anticancer therapy
• Local radiotherapy within 2 weeks prior to first dose of investigational drug
• Major surgery within 4 weeks prior to first dose of investigational drug
• Have any grade ≥ 2 residual toxicity according to Common Terminology Criteria for Adverse Events (CTCAE, version 5.0) from prior anti-tumor therapy (except alopecia and residual neurotoxicity).
• Clinically significant bleeding symptoms or obvious bleeding tendency within 1 month prior to the first dose
• Severe arteriovenous thrombotic events (e.g., deep venous thrombosis, pulmonary embolism) within 3 months prior to the first dose
• History of systemic glucocorticoids over 28 days prior to first dose of investigational drug
• Prior history of significant neurological or mental disorders, including conditions that interfere with assessment, such as epilepsy, dementia, or major depressive disorder.
• Past history of severe allergy, or history of hypersensitivity to any active or inactive ingredient of investigational drugs.

Other illness

• History of other primary malignancies
• Significant, uncontrolled, or active cardiovascular diseases
• Severe or poorly controlled diabetes
• Severe infection within 4 weeks
• Presence of known active infectious diseases,
• Presence of hepatic encephalopathy, Hepantorenal Syndrome
• Presence or history of confirmed or suspected ILD;
• Presence of any conditions that jeopardize subject safety or interfere with study assessments as judged by the investigator.

Lab values

• History of drugs may prolong QT interval

Other

• Pleural/abdominal effusion requires clinical intervention
• Presence of brain metastasis or carcinomatous meningtitis
• Extremely obesity or emaciation

• Cohort1:participants with EGFR mutation advanced stage NSCLC，disease progression on or after prior treatment；
• Cohort2:participants with MET position advanced stage NSCLC，disease progression on or after prior treatment；
• With at least 1 target lesion according to RECIST 1.1.
• Appropriate organ function
• Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0-1 and no deterioration within 2 weeks prior to the first dose.
• Minimum expected survival longer than 12 weeks
• Female subjects of childbearing potential are willing to take appropriate contraceptive measures and should not breastfeed from signing the informed consent form (ICF) through 6 months after the last dose; male subjects are willing to use barrier contraception (i.e., condom) from signing the ICF through 6 months after the last dose.
• Voluntarily participate in this clinical trial, understand the study procedures, and be able to sign written informed consent form.